Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A
Blood Vessels, Thrombosis & Hemostasis
· Elsevier
Аннотация
Publication date: November 2026 Source: Blood Vessels, Thrombosis & Hemostasis, Volume 3, Issue 4 Author(s): Carolina Costa-Lima, Vanessa B. Faiotto, Ana P. Francisco, Nívia M. Foschi, Samuel S. Medina, Marina P. Colella, Silmara A. Lima Montalvão, Gabriela G. Yamaguti-Hayakawa, Jéssica O. Frade-Guanaes, Margareth C. Ozelo
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Хирургия»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A. // Blood Vessels, Thrombosis & Hemostasis. – URL: https://www.sciencedirect.com/science/article/pii/S2950327226000653?dgcid=rss_sd_all
Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A. Blood Vessels, Thrombosis & Hemostasis. https://www.sciencedirect.com/science/article/pii/S2950327226000653?dgcid=rss_sd_all
“Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A.” Blood Vessels, Thrombosis & Hemostasis.
@article{article38721,
title = {Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A},
journal = {Blood Vessels, Thrombosis \& Hemostasis},
url = {https://www.sciencedirect.com/science/article/pii/S2950327226000653?dgcid=rss_sd_all}
}